vedolizumab-800CW

Vedolizumab-800CW is a fluorescently labeled version of vedolizumab (Entyvio) that has been developed for research purposes, specifically for fluorescence molecular imaging (FMI) to visualize drug distribution in inflammatory bowel disease (IBD) patients. **Description** Vedolizumab-800CW is a fluorescently labeled version of vedolizumab that has been developed to visualize the macroscopic and microscopic distribution of the drug in the gastrointestinal tract of IBD patients. This tracer allows researchers to track how vedolizumab penetrates inflamed tissues and binds to target cells, providing insights into its mechanism of action. The fluorescent labeling enables real-time visualization during endoscopy and subsequent microscopic analysis of tissue samples[2][5][9]. The drug has been used in clinical trials to study the distribution of vedolizumab in patients with inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Research has shown that vedolizumab-800CW penetrates the inflamed mucosa and associates with several immune cell types, most prominently with plasma cells[2][5][9]. **Development and Research Findings** Vedolizumab-800CW was developed and GMP-produced specifically for research purposes. In clinical trials, it has been administered intravenously at various doses (4.5 mg and 15 mg) to IBD patients, with the 15 mg dose showing the most suitable fluorescence intensity for imaging purposes[2][5][7]. Studies have demonstrated that the fluorescence signal decreases by approximately 61% when vedolizumab-80olizumab-800CW is administered after a therapeutic dose of unlabeled vedolizumab, suggesting target saturation in inflamed tissues[5][9]. Fluorescence microscopy and immunostaining have revealed that the drug penetrates the inflamed mucosa and binds to various immune cell types, with surface binding most prominent in plasma cells and intracellular localization primarily observed in macrophages and eosinophils[5][9]. This research provides valuable insights into how vedolizumab works in the body and may help improve patient selection and treatment strategies for IBD in the future.

Other names

fluorescent vedolizumab